Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 13Gastrointestinal 13Other solid neoplasm 6Head & Neck 4Breast 4Sarcoma 2Lymphoid 2Gynecologic 2Tumor-Agnostic 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Hematologic Neoplasms 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × camrelizumab × Other hematologic neoplasm × Clear all
NCT02492789 2019-09-30

A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients

Atridia Pty Ltd.

Phase 1 Completed
49 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡